CA3005775A1 - Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain - Google Patents

Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain Download PDF

Info

Publication number
CA3005775A1
CA3005775A1 CA3005775A CA3005775A CA3005775A1 CA 3005775 A1 CA3005775 A1 CA 3005775A1 CA 3005775 A CA3005775 A CA 3005775A CA 3005775 A CA3005775 A CA 3005775A CA 3005775 A1 CA3005775 A1 CA 3005775A1
Authority
CA
Canada
Prior art keywords
oxide derivative
opioid
oxide
composition
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3005775A
Other languages
English (en)
French (fr)
Inventor
Steve Whitelock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of CA3005775A1 publication Critical patent/CA3005775A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3005775A 2015-11-19 2016-11-18 Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain Abandoned CA3005775A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1520390.4 2015-11-19
GBGB1520390.4A GB201520390D0 (en) 2015-11-19 2015-11-19 Composition
PCT/GB2016/053600 WO2017085502A1 (en) 2015-11-19 2016-11-18 Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain

Publications (1)

Publication Number Publication Date
CA3005775A1 true CA3005775A1 (en) 2017-05-26

Family

ID=55133015

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3005775A Abandoned CA3005775A1 (en) 2015-11-19 2016-11-18 Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain

Country Status (14)

Country Link
US (1) US20180344726A1 (https=)
EP (1) EP3377048B1 (https=)
JP (1) JP2018534319A (https=)
KR (1) KR20180074797A (https=)
CN (1) CN108601747A (https=)
AU (1) AU2016355113A1 (https=)
BR (1) BR112018009886A2 (https=)
CA (1) CA3005775A1 (https=)
ES (1) ES2799516T3 (https=)
GB (1) GB201520390D0 (https=)
IL (1) IL259457A (https=)
MX (1) MX2018006157A (https=)
SG (1) SG11201803913RA (https=)
WO (1) WO2017085502A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7603583B2 (ja) * 2018-10-18 2024-12-20 アビオール、インコーポレイテッド 慢性腎疾患随伴掻痒を処置する方法及びデバイス

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722928A (en) * 1985-12-02 1988-02-02 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
HU229705B1 (en) * 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
GB0026137D0 (en) * 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
ES2283812T3 (es) * 2002-06-10 2007-11-01 Euro Celtique Sa Sistemas de eliminacion de dispositivos de adminsitracion transdemica para prevenir el uso indebido de los agentes activos contenidos en los mismos.
PT1718258E (pt) * 2004-02-23 2009-06-16 Euro Celtique Sa Dispositivo de administração transdérmica de opióides com resistência ao abuso
BRPI0719327A2 (pt) * 2006-11-22 2014-02-04 Progenics Pharm Inc N-óxidos de análogos de 4,5-epóxi-morfinano
WO2009067275A1 (en) * 2007-11-21 2009-05-28 Progenics Pharmaceuticals, Inc N-oxides of 4,5-epoxy-morphinanium analogs
JP2011515495A (ja) * 2008-03-26 2011-05-19 オールトランツ インコーポレイティド オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑制経皮製剤
US8829020B2 (en) * 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
JP2013523780A (ja) * 2010-04-02 2013-06-17 オールトランツ インコーポレイティド オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑止性経皮製剤

Also Published As

Publication number Publication date
IL259457A (en) 2018-07-31
JP2018534319A (ja) 2018-11-22
ES2799516T3 (es) 2020-12-18
CN108601747A (zh) 2018-09-28
SG11201803913RA (en) 2018-06-28
GB201520390D0 (en) 2016-01-06
AU2016355113A1 (en) 2018-05-24
MX2018006157A (es) 2019-04-04
EP3377048B1 (en) 2020-04-22
WO2017085502A1 (en) 2017-05-26
BR112018009886A2 (pt) 2018-11-13
EP3377048A1 (en) 2018-09-26
KR20180074797A (ko) 2018-07-03
US20180344726A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
JP5453151B2 (ja) 不正使用防止機能付きの経皮的オピオイド送給装置
US12582647B2 (en) Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US20080020028A1 (en) Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
JP2006501241A (ja) 活性剤及び塩並びに副作用物質の遊離塩基形を含む経皮剤形
US20200276187A1 (en) Systems and methods for attenuating opioid-induced euphoria
EP3377048B1 (en) Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain
US10226457B2 (en) Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US10406154B2 (en) Transdermal dosage form
WO2020009685A1 (en) Transdermal dosage form
WO2020008366A1 (en) Transdermal dosage form

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230209